Impact Factor 4.137 | CiteScore 4.28
More on impact ›
The acquisition of somatic genetic aberrations is central to the development of cancer, along with the constitutional genetic background of each patient in their cancer risk and response to therapy. Current technologies provide ever more powerful approaches to study and validate these highly complex phenomena. The Cancer Genetics specialty section will facilitate the publication of high-quality original research and review articles pertaining to the genetic, genomic and molecular aspects of cancer, and technical advances that facilitate progress in this field.
Focused primarily on molecular genetic aberrations driving malignant processes in human cancers, the scope of submissions will include investigations in the following areas:
Submissions not in scope for this specialty include:
Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Science Citation Index Expanded, CLOCKSS
PMCID: all published articles receive a PMCID
Cancer Genetics welcomes submissions of the following article types: Clinical Trial, Correction, Editorial, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Cancer Genetics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cancer Genetics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Genetics and Oncology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org